| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 18 | 2022 | 684 | 2.950 |
Why?
|
| Colorectal Neoplasms | 30 | 2024 | 3704 | 1.860 |
Why?
|
| Aspirin | 5 | 2022 | 392 | 1.200 |
Why?
|
| Neoplasms | 21 | 2022 | 15930 | 1.050 |
Why?
|
| PPAR gamma | 5 | 2006 | 231 | 0.980 |
Why?
|
| Hemostasis | 3 | 2022 | 99 | 0.820 |
Why?
|
| Cyclooxygenase 2 | 8 | 2018 | 498 | 0.700 |
Why?
|
| Biomarkers, Tumor | 18 | 2022 | 10750 | 0.630 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 5 | 2018 | 232 | 0.620 |
Why?
|
| Prostate | 6 | 2009 | 1138 | 0.600 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2022 | 640 | 0.580 |
Why?
|
| Prostaglandin D2 | 4 | 2005 | 26 | 0.560 |
Why?
|
| Adenoma | 2 | 2019 | 745 | 0.550 |
Why?
|
| Arachidonate 15-Lipoxygenase | 3 | 2006 | 94 | 0.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2022 | 545 | 0.550 |
Why?
|
| Isoenzymes | 3 | 2004 | 663 | 0.540 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2017 | 178 | 0.520 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 498 | 0.520 |
Why?
|
| Dinoprostone | 7 | 2018 | 222 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2020 | 9101 | 0.480 |
Why?
|
| Prostatic Neoplasms | 11 | 2011 | 5996 | 0.450 |
Why?
|
| Glycogen Synthase Kinase 3 | 3 | 2009 | 156 | 0.450 |
Why?
|
| Nanotechnology | 1 | 2014 | 137 | 0.450 |
Why?
|
| Platelet Activation | 1 | 2014 | 100 | 0.450 |
Why?
|
| Wound Healing | 1 | 2017 | 760 | 0.410 |
Why?
|
| Epoprostenol | 9 | 2018 | 86 | 0.400 |
Why?
|
| Pravastatin | 1 | 2011 | 33 | 0.400 |
Why?
|
| Simvastatin | 1 | 2011 | 100 | 0.380 |
Why?
|
| Endothelium | 7 | 2004 | 162 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 21 | 2013 | 5804 | 0.370 |
Why?
|
| Cell Adhesion | 16 | 2000 | 1041 | 0.360 |
Why?
|
| Cell Division | 5 | 2011 | 2711 | 0.350 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 3 | 2006 | 40 | 0.350 |
Why?
|
| Humans | 94 | 2024 | 272087 | 0.340 |
Why?
|
| Animals | 51 | 2022 | 62822 | 0.340 |
Why?
|
| Nerve Growth Factors | 7 | 1996 | 129 | 0.340 |
Why?
|
| Mutation | 14 | 2022 | 15944 | 0.330 |
Why?
|
| Chemoprevention | 3 | 2022 | 251 | 0.320 |
Why?
|
| Cell Line, Tumor | 21 | 2024 | 14881 | 0.300 |
Why?
|
| Prostaglandin-E Synthases | 2 | 2018 | 30 | 0.300 |
Why?
|
| Carcinoma | 1 | 2019 | 2623 | 0.290 |
Why?
|
| Immunomodulation | 2 | 2018 | 255 | 0.280 |
Why?
|
| Inflammation | 4 | 2022 | 2535 | 0.280 |
Why?
|
| Platelet Aggregation | 10 | 1990 | 183 | 0.280 |
Why?
|
| Melanoma | 12 | 2018 | 5592 | 0.260 |
Why?
|
| Neoplasms, Experimental | 5 | 2020 | 790 | 0.260 |
Why?
|
| Prostaglandins | 3 | 2018 | 84 | 0.260 |
Why?
|
| Cytoskeleton | 4 | 2021 | 304 | 0.260 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 194 | 0.260 |
Why?
|
| Selenium | 2 | 2006 | 51 | 0.250 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2005 | 88 | 0.240 |
Why?
|
| Microscopy, Fluorescence | 8 | 2011 | 782 | 0.240 |
Why?
|
| Carcinoma 256, Walker | 4 | 1987 | 9 | 0.240 |
Why?
|
| Adenocarcinoma | 7 | 2019 | 7976 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 852 | 0.230 |
Why?
|
| Sulindac | 2 | 2020 | 55 | 0.230 |
Why?
|
| Receptors, Prostaglandin | 2 | 2018 | 33 | 0.220 |
Why?
|
| Down-Regulation | 2 | 2006 | 2106 | 0.220 |
Why?
|
| Integrins | 4 | 2000 | 278 | 0.220 |
Why?
|
| Ki-67 Antigen | 3 | 2009 | 685 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2015 | 3651 | 0.220 |
Why?
|
| Cell Communication | 7 | 2014 | 518 | 0.220 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2004 | 109 | 0.220 |
Why?
|
| RNA, Long Noncoding | 2 | 2020 | 619 | 0.220 |
Why?
|
| Trifluridine | 1 | 2022 | 28 | 0.210 |
Why?
|
| Epithelium | 1 | 2005 | 805 | 0.210 |
Why?
|
| Anticarcinogenic Agents | 3 | 2017 | 372 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 232 | 0.200 |
Why?
|
| Growth Substances | 4 | 1996 | 329 | 0.200 |
Why?
|
| Signal Transduction | 16 | 2020 | 12223 | 0.200 |
Why?
|
| Biology | 1 | 2022 | 76 | 0.190 |
Why?
|
| Cardenolides | 2 | 2012 | 24 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2022 | 3929 | 0.190 |
Why?
|
| HCT116 Cells | 5 | 2021 | 354 | 0.190 |
Why?
|
| Transcriptome | 3 | 2020 | 1950 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 1483 | 0.190 |
Why?
|
| Colonic Neoplasms | 3 | 2019 | 1443 | 0.180 |
Why?
|
| Support Vector Machine | 1 | 2020 | 42 | 0.180 |
Why?
|
| Megakaryocytes | 1 | 2021 | 131 | 0.180 |
Why?
|
| Cetuximab | 3 | 2017 | 474 | 0.180 |
Why?
|
| Carcinoma in Situ | 2 | 2001 | 496 | 0.180 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 2012 | 138 | 0.180 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 135 | 0.180 |
Why?
|
| Mammals | 1 | 2022 | 374 | 0.170 |
Why?
|
| Karyopherins | 1 | 2021 | 134 | 0.170 |
Why?
|
| Cyclopentanes | 1 | 2020 | 43 | 0.170 |
Why?
|
| Transfection | 8 | 2009 | 3166 | 0.170 |
Why?
|
| Genomics | 2 | 2021 | 2830 | 0.170 |
Why?
|
| Thromboxane-A Synthase | 3 | 2018 | 26 | 0.170 |
Why?
|
| Neoplasm Metastasis | 11 | 2019 | 5330 | 0.170 |
Why?
|
| Chromosomal Instability | 1 | 2020 | 230 | 0.170 |
Why?
|
| Male | 35 | 2022 | 129088 | 0.160 |
Why?
|
| Antineoplastic Agents | 10 | 2020 | 14653 | 0.160 |
Why?
|
| Blotting, Western | 7 | 2015 | 3646 | 0.160 |
Why?
|
| Serum Albumin, Bovine | 1 | 2019 | 84 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 1615 | 0.160 |
Why?
|
| Cell Nucleus | 2 | 2007 | 1740 | 0.160 |
Why?
|
| Lipoxygenase | 1 | 2018 | 26 | 0.160 |
Why?
|
| Oncogenes | 1 | 2022 | 701 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 437 | 0.160 |
Why?
|
| MicroRNAs | 3 | 2022 | 2913 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 159 | 0.160 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 68 | 0.160 |
Why?
|
| Cells, Cultured | 9 | 2013 | 5788 | 0.150 |
Why?
|
| Cell-Derived Microparticles | 1 | 2018 | 39 | 0.150 |
Why?
|
| Carcinogenesis | 3 | 2022 | 1037 | 0.150 |
Why?
|
| Gene Amplification | 2 | 2016 | 770 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2019 | 180 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2020 | 221 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2017 | 2383 | 0.150 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 364 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2009 | 40 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 284 | 0.150 |
Why?
|
| Extracellular Matrix Proteins | 2 | 1997 | 303 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2001 | 1237 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 81 | 0.150 |
Why?
|
| Cell Proliferation | 9 | 2017 | 7302 | 0.140 |
Why?
|
| Cyclooxygenase 1 | 1 | 2017 | 68 | 0.140 |
Why?
|
| Glucuronidase | 2 | 1994 | 54 | 0.140 |
Why?
|
| Prognosis | 11 | 2020 | 22555 | 0.140 |
Why?
|
| Extracellular Matrix | 5 | 1995 | 534 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 1143 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2017 | 220 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 203 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 342 | 0.140 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 642 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2019 | 531 | 0.140 |
Why?
|
| Phosphorylation | 7 | 2015 | 4984 | 0.140 |
Why?
|
| Liver Neoplasms | 6 | 2021 | 4811 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2001 | 1707 | 0.140 |
Why?
|
| Microsatellite Instability | 4 | 2020 | 410 | 0.130 |
Why?
|
| Microsomes | 1 | 2016 | 77 | 0.130 |
Why?
|
| Transcriptional Activation | 3 | 2005 | 1146 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 573 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 4963 | 0.130 |
Why?
|
| RNA Interference | 3 | 2015 | 1397 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 2624 | 0.130 |
Why?
|
| Silicon | 1 | 2015 | 48 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 2 | 2009 | 252 | 0.130 |
Why?
|
| Mice | 24 | 2021 | 36053 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 253 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2019 | 1066 | 0.120 |
Why?
|
| Glucose | 2 | 2018 | 1246 | 0.120 |
Why?
|
| Neoplasm Proteins | 6 | 2011 | 3363 | 0.120 |
Why?
|
| Apoptosis | 6 | 2011 | 7837 | 0.120 |
Why?
|
| Fluoroscopy | 1 | 2015 | 225 | 0.120 |
Why?
|
| Densitometry | 2 | 2005 | 52 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 1026 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 1409 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2014 | 53 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2010 | 1230 | 0.120 |
Why?
|
| Biocompatible Materials | 2 | 2014 | 201 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 487 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 298 | 0.120 |
Why?
|
| Consensus | 1 | 2019 | 1116 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 16612 | 0.110 |
Why?
|
| Brain Neoplasms | 6 | 2000 | 4994 | 0.110 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 272 | 0.110 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 23 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2004 | 162 | 0.110 |
Why?
|
| Cytokines | 3 | 2018 | 2841 | 0.110 |
Why?
|
| Sulfonamides | 5 | 2022 | 1919 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 4496 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 428 | 0.110 |
Why?
|
| Dasatinib | 1 | 2017 | 881 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2006 | 2457 | 0.110 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 7476 | 0.110 |
Why?
|
| Pancreatic Stellate Cells | 1 | 2013 | 78 | 0.110 |
Why?
|
| Tissue Distribution | 3 | 2019 | 946 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 277 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 5213 | 0.100 |
Why?
|
| Cell Survival | 8 | 2016 | 3074 | 0.100 |
Why?
|
| Precancerous Conditions | 2 | 2017 | 1065 | 0.100 |
Why?
|
| Receptors, Nerve Growth Factor | 4 | 1996 | 39 | 0.100 |
Why?
|
| Liposomes | 1 | 2014 | 711 | 0.100 |
Why?
|
| RNA, Messenger | 6 | 2017 | 6489 | 0.100 |
Why?
|
| Nitrobenzenes | 2 | 2003 | 32 | 0.100 |
Why?
|
| Colon | 4 | 2020 | 691 | 0.100 |
Why?
|
| Transglutaminases | 2 | 1993 | 100 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2022 | 203 | 0.100 |
Why?
|
| Endothelium, Vascular | 3 | 1999 | 898 | 0.100 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 46 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1197 | 0.100 |
Why?
|
| Epithelial Cells | 3 | 2008 | 1892 | 0.100 |
Why?
|
| Cell Movement | 5 | 2017 | 2504 | 0.100 |
Why?
|
| beta Catenin | 1 | 2015 | 691 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 1004 | 0.100 |
Why?
|
| Middle Aged | 18 | 2022 | 90460 | 0.090 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2011 | 27 | 0.090 |
Why?
|
| Chromans | 1 | 2011 | 29 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 460 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2009 | 2085 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7958 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2021 | 3664 | 0.090 |
Why?
|
| Disease Progression | 3 | 2018 | 6911 | 0.090 |
Why?
|
| Cell Death | 4 | 2004 | 689 | 0.090 |
Why?
|
| Vitamin E | 1 | 2011 | 131 | 0.090 |
Why?
|
| Morpholines | 2 | 2021 | 296 | 0.090 |
Why?
|
| Luciferases | 3 | 2010 | 464 | 0.090 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1995 | 550 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 1389 | 0.090 |
Why?
|
| Neutrophils | 1 | 2015 | 876 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 1501 | 0.090 |
Why?
|
| Female | 21 | 2022 | 149288 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 591 | 0.090 |
Why?
|
| Cell Line | 8 | 2009 | 5433 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 665 | 0.090 |
Why?
|
| Proteomics | 1 | 2017 | 1437 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3671 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2015 | 1280 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3395 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2017 | 3417 | 0.080 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 340 | 0.080 |
Why?
|
| Membrane Proteins | 4 | 2004 | 2975 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 390 | 0.080 |
Why?
|
| alpha-Tocopherol | 1 | 2009 | 80 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2000 | 130 | 0.080 |
Why?
|
| Contrast Media | 1 | 2015 | 1510 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 2649 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2011 | 448 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2009 | 282 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 1996 | 1599 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 10365 | 0.080 |
Why?
|
| Protein Binding | 3 | 2018 | 3528 | 0.080 |
Why?
|
| Mice, Nude | 4 | 2019 | 4360 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 399 | 0.080 |
Why?
|
| Bronchial Neoplasms | 1 | 2008 | 83 | 0.070 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1987 | 64 | 0.070 |
Why?
|
| Arachidonic Acid | 3 | 2005 | 119 | 0.070 |
Why?
|
| Eicosanoic Acids | 1 | 1987 | 4 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 6885 | 0.070 |
Why?
|
| HT29 Cells | 2 | 2021 | 157 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 1599 | 0.070 |
Why?
|
| Cytoplasmic Granules | 2 | 1987 | 87 | 0.070 |
Why?
|
| Hypoxia | 1 | 2010 | 477 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2017 | 9500 | 0.070 |
Why?
|
| Receptors, Vitronectin | 2 | 1997 | 28 | 0.070 |
Why?
|
| Biomarkers | 1 | 2018 | 5115 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 1085 | 0.070 |
Why?
|
| Bronchi | 1 | 2008 | 330 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2006 | 25 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 1997 | 6783 | 0.070 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 4371 | 0.070 |
Why?
|
| DNA, Neoplasm | 4 | 2017 | 1972 | 0.070 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 128 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2022 | 637 | 0.070 |
Why?
|
| Models, Biological | 2 | 2014 | 3223 | 0.070 |
Why?
|
| Receptor Cross-Talk | 1 | 2006 | 81 | 0.070 |
Why?
|
| Aged | 13 | 2022 | 73517 | 0.070 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 99 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2009 | 1077 | 0.070 |
Why?
|
| GTP-Binding Proteins | 2 | 2005 | 347 | 0.060 |
Why?
|
| Fibronectins | 3 | 1997 | 210 | 0.060 |
Why?
|
| Risk | 1 | 2010 | 1950 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 4890 | 0.060 |
Why?
|
| Lipocalins | 1 | 2005 | 55 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 2003 | 735 | 0.060 |
Why?
|
| Cadherins | 2 | 2017 | 676 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 533 | 0.060 |
Why?
|
| Culture Media | 2 | 2005 | 349 | 0.060 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.060 |
Why?
|
| Luminescent Agents | 1 | 2004 | 18 | 0.060 |
Why?
|
| Base Sequence | 4 | 1995 | 5502 | 0.060 |
Why?
|
| DNA Methylation | 3 | 2021 | 2761 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 15279 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 5107 | 0.060 |
Why?
|
| Luciferases, Firefly | 1 | 2004 | 41 | 0.060 |
Why?
|
| Indomethacin | 2 | 2000 | 115 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 2474 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 584 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 5187 | 0.060 |
Why?
|
| Oligopeptides | 2 | 1997 | 451 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2017 | 2496 | 0.060 |
Why?
|
| Adult | 11 | 2021 | 81933 | 0.060 |
Why?
|
| Cell Compartmentation | 1 | 2004 | 91 | 0.060 |
Why?
|
| Alprostadil | 1 | 2004 | 37 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2010 | 2150 | 0.060 |
Why?
|
| Glycoside Hydrolases | 2 | 1994 | 42 | 0.060 |
Why?
|
| Tyrosine | 2 | 2022 | 510 | 0.060 |
Why?
|
| Rats | 9 | 1997 | 6640 | 0.060 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2006 | 504 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 1458 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 358 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 319 | 0.060 |
Why?
|
| Chromones | 1 | 2003 | 121 | 0.060 |
Why?
|
| Stress, Mechanical | 2 | 1997 | 275 | 0.060 |
Why?
|
| Recurrence | 2 | 2024 | 4887 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1987 | 483 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 668 | 0.050 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2004 | 95 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1061 | 0.050 |
Why?
|
| Cattle | 1 | 2004 | 846 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 3262 | 0.050 |
Why?
|
| Phenotype | 1 | 2014 | 6517 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 1987 | 245 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 196 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2002 | 16244 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 1091 | 0.050 |
Why?
|
| Genetic Variation | 2 | 2017 | 2157 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 1999 | 1737 | 0.050 |
Why?
|
| Ligands | 1 | 2005 | 1057 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 7828 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2004 | 860 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 7 | 2017 | 4071 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 394 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 955 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 162 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2022 | 152 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2005 | 835 | 0.050 |
Why?
|
| Time Factors | 5 | 2015 | 13139 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 228 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 212 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2009 | 1720 | 0.050 |
Why?
|
| Sodium Selenite | 1 | 2000 | 2 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 10259 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 5421 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2001 | 262 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 212 | 0.050 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 810 | 0.050 |
Why?
|
| Azoxymethane | 1 | 2020 | 43 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2018 | 2035 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2355 | 0.040 |
Why?
|
| Aurora Kinase B | 1 | 2020 | 68 | 0.040 |
Why?
|
| Survival Rate | 3 | 2019 | 12534 | 0.040 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| Drug Design | 1 | 2002 | 378 | 0.040 |
Why?
|
| Dextrans | 1 | 2020 | 99 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 680 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2021 | 150 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 384 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2020 | 102 | 0.040 |
Why?
|
| Peptides | 2 | 2003 | 1529 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 381 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 203 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 169 | 0.040 |
Why?
|
| Microfluidics | 1 | 2019 | 32 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 465 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1999 | 30 | 0.040 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 12012 | 0.040 |
Why?
|
| Carcinoma, Embryonal | 1 | 1999 | 31 | 0.040 |
Why?
|
| Interferon Type I | 1 | 2000 | 283 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 376 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2019 | 237 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 277 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 574 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 100 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2003 | 1756 | 0.040 |
Why?
|
| Binding Sites | 1 | 2002 | 2298 | 0.040 |
Why?
|
| Melanoma, Experimental | 2 | 1994 | 385 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 909 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 1442 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 3512 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 1966 | 0.040 |
Why?
|
| Microscopy, Electron | 3 | 1988 | 735 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2012 | 4195 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 517 | 0.040 |
Why?
|
| Organoids | 1 | 2020 | 325 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 751 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1999 | 374 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2018 | 273 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 13993 | 0.040 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 61 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3546 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2002 | 695 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 1566 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 4200 | 0.040 |
Why?
|
| Thrombocytosis | 1 | 2018 | 142 | 0.040 |
Why?
|
| Naphthalenes | 2 | 2013 | 84 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2018 | 248 | 0.030 |
Why?
|
| Trans-Activators | 2 | 2000 | 1660 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2015 | 2470 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 5196 | 0.030 |
Why?
|
| Age of Onset | 1 | 2019 | 855 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2017 | 167 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2016 | 51 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 408 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 344 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2019 | 39831 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 1469 | 0.030 |
Why?
|
| Computational Biology | 1 | 2022 | 1282 | 0.030 |
Why?
|
| Eicosanoids | 1 | 2015 | 30 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6210 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 22142 | 0.030 |
Why?
|
| COP9 Signalosome Complex | 1 | 2015 | 80 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 845 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 31066 | 0.030 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1996 | 191 | 0.030 |
Why?
|
| Indoles | 1 | 2021 | 1034 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 479 | 0.030 |
Why?
|
| Urinary Catheters | 1 | 2015 | 34 | 0.030 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 48 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 267 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2018 | 527 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2013 | 352 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 1997 | 4635 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 2017 | 261 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 497 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 2259 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1995 | 209 | 0.030 |
Why?
|
| DNA-Binding Proteins | 3 | 2009 | 5067 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1997 | 682 | 0.030 |
Why?
|
| Software | 1 | 2021 | 1387 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2867 | 0.030 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 1994 | 19 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 704 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2000 | 5603 | 0.030 |
Why?
|
| Receptors, Neuropeptide | 1 | 1994 | 28 | 0.030 |
Why?
|
| Gelatinases | 1 | 1994 | 53 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 1988 | 557 | 0.030 |
Why?
|
| Colchicine | 2 | 1987 | 72 | 0.030 |
Why?
|
| Pyridines | 1 | 2021 | 1312 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 7237 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 738 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 442 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 1323 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2009 | 304 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 1996 | 685 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 2 | 2009 | 5248 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 2365 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 2219 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2015 | 577 | 0.030 |
Why?
|
| Phenylbutyrates | 1 | 2013 | 63 | 0.030 |
Why?
|
| Prostatectomy | 2 | 2009 | 1006 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4513 | 0.030 |
Why?
|
| DNA Damage | 1 | 2000 | 1989 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 161 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 857 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2017 | 1988 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 191 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 261 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2152 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2000 | 2472 | 0.020 |
Why?
|
| Laminin | 2 | 2007 | 214 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1556 | 0.020 |
Why?
|
| Cadaverine | 1 | 1991 | 7 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 48 | 0.020 |
Why?
|
| Autoradiography | 1 | 1991 | 158 | 0.020 |
Why?
|
| Cytoplasm | 2 | 2007 | 719 | 0.020 |
Why?
|
| Proteoglycans | 2 | 2007 | 278 | 0.020 |
Why?
|
| Lymphoma | 1 | 2000 | 1514 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1659 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 1999 | 3078 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1997 | 1547 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2319 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 611 | 0.020 |
Why?
|
| Cell Membrane | 3 | 1993 | 900 | 0.020 |
Why?
|
| Calcium | 1 | 1996 | 1594 | 0.020 |
Why?
|
| Thiophenes | 1 | 1991 | 148 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 1990 | 153 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2958 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3544 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 194 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 718 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 2 | 2000 | 162 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2010 | 265 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 1330 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1991 | 387 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 569 | 0.020 |
Why?
|
| Microdissection | 1 | 2009 | 86 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 201 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2017 | 1207 | 0.020 |
Why?
|
| Mucins | 1 | 1990 | 289 | 0.020 |
Why?
|
| Collagen | 2 | 2007 | 739 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 1005 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 593 | 0.020 |
Why?
|
| Liver | 1 | 1999 | 3123 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2576 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2009 | 177 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 5864 | 0.020 |
Why?
|
| Aurora Kinase A | 1 | 2010 | 212 | 0.020 |
Why?
|
| Fishes | 2 | 1978 | 55 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2357 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 32730 | 0.020 |
Why?
|
| Cytochalasins | 1 | 1987 | 2 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1987 | 42 | 0.020 |
Why?
|
| Gene Expression | 2 | 2013 | 3690 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2000 | 5506 | 0.020 |
Why?
|
| Cell Extracts | 1 | 1987 | 67 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 968 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 1987 | 44 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 4968 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 1987 | 44 | 0.020 |
Why?
|
| Prevalence | 1 | 1995 | 3427 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 202 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 909 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 1987 | 62 | 0.020 |
Why?
|
| Vitronectin | 2 | 1997 | 24 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 320 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2006 | 157 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 1102 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 9326 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 207 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 1433 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2011 | 1004 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6270 | 0.020 |
Why?
|
| Protein Kinase C | 2 | 1997 | 419 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2337 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 1986 | 265 | 0.010 |
Why?
|
| Neurons | 1 | 1995 | 2462 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1987 | 1742 | 0.010 |
Why?
|
| Celecoxib | 1 | 2004 | 203 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 1668 | 0.010 |
Why?
|
| Pyrazolones | 1 | 1983 | 5 | 0.010 |
Why?
|
| Organ Specificity | 2 | 1996 | 755 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2369 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5756 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2003 | 138 | 0.010 |
Why?
|
| Carcinosarcoma | 1 | 1984 | 149 | 0.010 |
Why?
|
| Melanophores | 2 | 1978 | 2 | 0.010 |
Why?
|
| Arachidonic Acids | 2 | 1997 | 34 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2003 | 264 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1622 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2002 | 6236 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1581 | 0.010 |
Why?
|
| United States | 1 | 2019 | 16066 | 0.010 |
Why?
|
| Lung | 1 | 2012 | 3295 | 0.010 |
Why?
|
| Calcium Channel Blockers | 2 | 1996 | 145 | 0.010 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2000 | 7 | 0.010 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2000 | 7 | 0.010 |
Why?
|
| STAT2 Transcription Factor | 1 | 2000 | 5 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 2000 | 15 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 4257 | 0.010 |
Why?
|
| Oncostatin M | 1 | 2000 | 22 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2000 | 49 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 139 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 3543 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 188 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 164 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 278 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 33909 | 0.010 |
Why?
|
| Mucoproteins | 1 | 1999 | 25 | 0.010 |
Why?
|
| Lymphokines | 1 | 2000 | 317 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1999 | 89 | 0.010 |
Why?
|
| Integrin alpha4beta1 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Chromatophores | 1 | 1978 | 2 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 1155 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 1999 | 170 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1999 | 230 | 0.010 |
Why?
|
| Pyrazoles | 2 | 2004 | 1544 | 0.010 |
Why?
|
| Epidermis | 1 | 1978 | 200 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1072 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1999 | 289 | 0.010 |
Why?
|
| Sphingosine | 1 | 1997 | 59 | 0.010 |
Why?
|
| Vinblastine | 1 | 1978 | 462 | 0.010 |
Why?
|
| Rheology | 1 | 1997 | 47 | 0.010 |
Why?
|
| Fura-2 | 1 | 1996 | 19 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 1996 | 22 | 0.010 |
Why?
|
| Cations | 1 | 1996 | 60 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1997 | 223 | 0.010 |
Why?
|
| Actin Cytoskeleton | 1 | 1996 | 79 | 0.010 |
Why?
|
| Gliosis | 1 | 1996 | 44 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 582 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2001 | 2335 | 0.010 |
Why?
|
| Calmodulin | 1 | 1996 | 264 | 0.010 |
Why?
|
| Actins | 1 | 1978 | 617 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1996 | 404 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 3089 | 0.010 |
Why?
|
| Skin | 1 | 2000 | 1284 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 1996 | 250 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 209 | 0.010 |
Why?
|
| Collagenases | 1 | 1993 | 75 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1997 | 1832 | 0.010 |
Why?
|
| Receptor, trkA | 1 | 1993 | 41 | 0.010 |
Why?
|
| Blood Coagulation | 2 | 1986 | 168 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1993 | 142 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1993 | 145 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2000 | 1146 | 0.010 |
Why?
|
| Astrocytes | 1 | 1996 | 407 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1996 | 815 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1997 | 1327 | 0.010 |
Why?
|
| Solubility | 1 | 1990 | 251 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1990 | 727 | 0.010 |
Why?
|
| Epinephrine | 2 | 1978 | 249 | 0.000 |
Why?
|
| Microtubules | 2 | 1978 | 330 | 0.000 |
Why?
|
| Prostaglandins D | 1 | 1986 | 1 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1996 | 5841 | 0.000 |
Why?
|
| Cricetinae | 1 | 1986 | 793 | 0.000 |
Why?
|
| Blood Vessels | 1 | 1986 | 239 | 0.000 |
Why?
|
| Endopeptidases | 1 | 1986 | 233 | 0.000 |
Why?
|
| Rabbits | 1 | 1986 | 1077 | 0.000 |
Why?
|
| Thromboxanes | 1 | 1983 | 14 | 0.000 |
Why?
|
| Thromboxane A2 | 1 | 1983 | 27 | 0.000 |
Why?
|
| Cathepsin B | 1 | 1983 | 35 | 0.000 |
Why?
|
| Cathepsins | 1 | 1983 | 56 | 0.000 |
Why?
|
| Serotonin | 1 | 1983 | 290 | 0.000 |
Why?
|
| Thrombocytopenia | 1 | 1986 | 872 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1986 | 967 | 0.000 |
Why?
|
| Cytoplasmic Streaming | 1 | 1978 | 1 | 0.000 |
Why?
|
| Theophylline | 1 | 1978 | 36 | 0.000 |
Why?
|
| Killifishes | 1 | 1978 | 1 | 0.000 |
Why?
|